Skip to content
Search

Latest Stories

Being overweight linked with risk of multiple diseases: Study

Researchers have found the strongest evidence yet of a causal relationship between obesity and a wide range of serious conditions, including cardiovascular disease, diabetes, cancer, and neurological, musculoskeletal and respiratory afflictions.

The study, published in the journal Lancet Digital Health, draws data from the UK Biobank—a research database holding health and genetic information from half a million volunteers—to analyse associations between body mass index (BMI) and a range of disease outcomes in 337,536 people.


"In this study we used a genetic approach to seek evidence for true health effects associated with higher body mass index, which assesses our weight against our height and is commonly used to measure obesity," said Professor Elina Hypponen from the University of South Australia.

Previous research has suggested that high BMI is associated with increased risk of chronic diseases such as type 2 diabetes, cardiovascular disease and cancer, but due to the difficulty of conducting clinical trials related to obesity, it has been hard to prove causation.

Hypponen and her team developed a multi-dimensional analysis in which genetic data was subjected to a suite of stringent examinations in order to deliver high confidence of causality.

"We compared evidence from five different statistical approaches to establish how strong the evidence for causal effect actually is," she said.

"Fully consistent evidence across all approaches was seen for 14 different diseases, and for 26 different diseases evidence was obtained by at least for four of the five methods used," Hypponen said.

"What increases the confidence that these associations are largely reflective of real effects is the fact that those effects which came across with consistent evidence are also ones for which we have previous clinical evidence," he said.

One key finding from the study was the extent to which it confirms existing concerns over the link between obesity and diabetes, with many of the diseases identified as related to high BMI known to be commonly associated with poorly controlled diabetes.

"For example, we saw evidence for effects on peripheral nerve disorders, chronic leg and foot ulcers, and even gangrene and kidney failure, which are all known to be diabetic complications.

"This suggests a key aspect to reduce comorbidity risk in obesity is careful monitoring of blood sugar and effective control of diabetes and its complications," Hypponen said.

The study also highlights the importance of genetic research to further our understanding of the role genes play in obesity, and the insights it can provide for the future management and treatment of obesity.

"There is an urgent need to find new approaches to manage and prevent obesity," Hypponen said.

"We know that obesity has a strong genetic basis, which can make weight management very difficult to some of us and the same strategies for prevention may also not work for all.

"Genetic studies are giving us deeper insights into the biological pathways which drive obesity, and hopefully these types of studies will also provide us with new strategies for prevention," she said.

More For You

Camellia Panjabi's cookbook elevates
vegetables from sides to stars

Camellia Panjabi (Photo: Ursula Sierek)

Camellia Panjabi's cookbook elevates vegetables from sides to stars

RESTAURATEUR and writer Camellia Panjabi puts the spotlight on vegetables in her new book, as she said they were never given the status of a “hero” in the way fish, chicken or prawns are.

Panjabi’s Vegetables: The Indian Way features more than 120 recipes, with notes on nutrition, Ayurvedic insights and cooking methods that support digestion.

Keep ReadingShow less
Spotting the signs of dementia

Priya Mulji with her father

Spotting the signs of dementia

How noticing the changes in my father taught me the importance of early action, patience, and love

I don’t understand people who don’t talk or see their parents often. Unless they have done something to ruin your lives or you had a traumatic childhood, there is no reason you shouldn’t be checking in with them at least every few days if you don’t live with them.

Keep ReadingShow less
HH Guruji performed the Dhwaja Ritual at Ambaji Temple

HH Guruji performed the Dhwaja Ritual at Ambaji Temple

Mahesh Liloriya

The holy town of Ambaji witnessed a spiritually significant day on Sunday as His Holiness Siri Rajrajeshwar Guruji, head of the International Siddhashram Shakti Centre, London, performed the Dhwaja ritual at the historic Ambaji Temple in Gujarat, one of the most revered Shakti Peeths of India.

Keep ReadingShow less
Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Eco-friendly Ganesh Utsav at Harrow’s Siddhashram Shakti Centre

Mahesh Liloriya

The International Siddhashram Shakti Centre in Harrow witnessed an inspiring and environmentally responsible celebration of Ganesh Utsav 2025, which concluded on Saturday, 6 September, with the Ganesh Visarjan ritual performed on the sacred occasion of Anant Chaturdashi.

Keep ReadingShow less
Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less